Literature DB >> 12165659

Chromogranin A and chromogranin B in noninvasive and invasive breast carcinoma.

Noriko Kimura1, Ryuichi Yoshida, Shin-ichiro Shiraishi, Monika Pilichowska, Noriaki Ohuchi.   

Abstract

Recent progress in the study of chromogranins has revealed that there are many novel peptides derived from chromogranin with their multiple pathophysiologic roles. To learn the possible roles of chromogranin in breast carcinoma, we immunohistochemically investigated tissue localization of chromogranin A (CgA) and chromogranin B (CgB) in 10 normal breast tissues, 23 noninvasive ductal carcinomas (NIDCs), and 169 invasive ductal carcinomas (IDCs) and compared their expression with estrogen receptor (ER), progesterone receptor (PR), and Ki67. CgA and CgB were sporadically detected in normal cells of the ducts, acini, and luminal secretion. The expression of CgA and CgB was higher in NIDCs than in IDCs: CgA = 70% of NIDC vs 22% of IDC and CgB = 65% of NIDC vs 30% of IDC. There was a statistical correlation between the expression of CgA and PR (p < 0.05) and CgB and ER (p < 0.05) in IDCs without lymph node metastasis. On the other hand, there was a significant correlation between expression of CgB and PR and an inverse correlation between CgA and Ki67 in IDCs of overall cases. The data suggest that CgA and CgB may play some role in the early phase of neoplastic progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165659     DOI: 10.1385/ep:13:2:117

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  20 in total

1.  Prevalence and prognostic significance of neuroendocrine cells in esophageal adenocarcinoma.

Authors:  K Hamilton; A Chiappori; S Olson; J Sawyers; D Johnson; K Washington
Journal:  Mod Pathol       Date:  2000-05       Impact factor: 7.842

2.  Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors.

Authors:  R V Lloyd; M Cano; P Rosa; A Hille; W B Huttner
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

3.  Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases.

Authors:  M Papotti; L Macrì; G Finzi; C Capella; V Eusebi; G Bussolati
Journal:  Semin Diagn Pathol       Date:  1989-05       Impact factor: 3.464

4.  Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A.

Authors:  K Lugardon; R Raffner; Y Goumon; A Corti; A Delmas; P Bulet; D Aunis; M H Metz-Boutigue
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

5.  Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma.

Authors:  G MacGrogan; I Jollet; S Huet; G Sierankowski; V Picot; F Bonichon; J M Coindre
Journal:  Mod Pathol       Date:  1997-08       Impact factor: 7.842

6.  Argyrophilia and granin (chromogranin/secretogranin) expression in female breast carcinomas. Their relationship to survival and other disease parameters.

Authors:  L Scopsi; S Andreola; S Pilotti; A Testori; M T Baldini; F Leoni; L Lombardi; J C Hutton; F Shimizu; P Rosa
Journal:  Am J Surg Pathol       Date:  1992-06       Impact factor: 6.394

7.  "Carcinoid" tumor of the breast. A variant of conventional breast cancer?

Authors:  J B Taxy; A S Tischler; S J Insalaco; H Battifora
Journal:  Hum Pathol       Date:  1981-02       Impact factor: 3.466

8.  Chromogranin A and B gene expression in carcinomas of the breast. Correlation of immunocytochemical, immunoblot, and hybridization analyses.

Authors:  A Pagani; M Papotti; H Höfler; R Weiler; H Winkler; G Bussolati
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

9.  Chromogranin-reactive endocrine cells in argyrophilic carcinomas ("carcinoids") and normal tissue of the breast.

Authors:  G Bussolati; P Gugliotta; A Sapino; V Eusebi; R V Lloyd
Journal:  Am J Pathol       Date:  1985-08       Impact factor: 4.307

10.  Endocrine markers in argyrophilic carcinomas of the breast.

Authors:  G Bussolati; M Papotti; A Sapino; P Gugliotta; B Ghiringhello; J G Azzopardi
Journal:  Am J Surg Pathol       Date:  1987-04       Impact factor: 6.394

View more
  8 in total

1.  Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas.

Authors:  Sheng-Yuan Yu; Li-Chuan Hong; Jie Feng; You-Tu Wu; Ya-Zhuo Zhang
Journal:  Tumour Biol       Date:  2016-01-11

Review 2.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 3.  Chromogranin A and the tumor microenvironment.

Authors:  Angelo Corti
Journal:  Cell Mol Neurobiol       Date:  2010-11-16       Impact factor: 5.046

4.  Cancer outlier detection based on likelihood ratio test.

Authors:  Jianhua Hu
Journal:  Bioinformatics       Date:  2008-08-12       Impact factor: 6.937

5.  Gene network inference and biochemical assessment delineates GPCR pathways and CREB targets in small intestinal neuroendocrine neoplasia.

Authors:  Ignat Drozdov; Bernhard Svejda; Bjorn I Gustafsson; Shrikant Mane; Roswitha Pfragner; Mark Kidd; Irvin M Modlin
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

6.  Clinical and genomic analyses of neuroendocrine neoplasms of the breast.

Authors:  Yani Wei; Xuexuan Ke; Jiaxiu Yu; Qiuyang Jing; Hong Bu; Xiangfei Zeng; Bing Wei
Journal:  Mod Pathol       Date:  2021-11-02       Impact factor: 7.842

7.  Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways.

Authors:  Arsalan Amirfallah; Hildur Knutsdottir; Adalgeir Arason; Bylgja Hilmarsdottir; Oskar T Johannsson; Bjarni A Agnarsson; Rosa B Barkardottir; Inga Reynisdottir
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

8.  Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.

Authors:  Masayuki Hijioka; Tetsuhide Ito; Hisato Igarashi; Nao Fujimori; Lingaku Lee; Taichi Nakamura; Robert T Jensen; Ryoichi Takayanagi
Journal:  Cancer Sci       Date:  2014-10-18       Impact factor: 6.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.